Novo Nordisk to present new semaglutide data on ‘food noise', body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress
1. Novo Nordisk presents 35 abstracts on diabetes and obesity at EASD congress. 2. Semaglutide shows significant health benefits and broad approved indications. 3. Next-generation treatment cagrilintide shows promising efficacy as standalone therapy. 4. Ozempic demonstrated superiority over dulaglutide in reducing cardiovascular events. 5. Novo Nordisk hosts an R&D investor event during EASD for stakeholders.